Here are the 424B prospectus supplements from Maze Therapeutics, Inc. (MAZE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics, Inc. is conducting a primary offering of 5,540,000 shares of common stock and pre-funded warrants to purchase 850,000 shares of common stock, as set forth in the prospectus supplement. The offering price is $23.50 per share (pre-funded warrant exercise price $0.001). Estimated gross proceeds are $150.16M and estimated net proceeds to the company are approximately $144.7M after underwriting discounts. The company reported 49,335,551 shares outstanding as of December 31, 2025. Proceeds are intended to fund R&D (including MZE829 and MZE782) and general corporate purposes; management has broad discretion over use of proceeds.
Maze Therapeutics, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 9,231,092 shares of common stock by selling stockholders. This includes 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants issued in a September 2025 private placement.
The company is not selling any securities in this prospectus and will not receive proceeds from sales by the holders. Upon any cash exercise of the pre-funded warrants (exercise price $0.001 per share), the company would receive the exercise price. The shares may be sold at market or negotiated prices through brokers, dealers, agents, or direct sales. The warrants include a 4.99% or 9.99% beneficial ownership cap. As context, shares outstanding were 48,076,885 as of September 30, 2025. Examples of registered resale amounts include Entities Affiliated with Baker Brothers 1,538,556 and Janus Henderson 1,230,769. Common stock trades on Nasdaq as MAZE.